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Abstract
Background: Pulmonary arterial hypertension (PAH) is a severe lung disease with only few effective treatments
available. Familial cases of PAH are usually recognized as an autosomal dominant disease, but incomplete
penetrance of the disease makes it difficult to identify pathogenic variants in accordance with a Mendelian
pattern of inheritance.
Methods: To elucidate the complex genetic basis of PAH, we obtained whole exome- or genome-sequencing data of
17 subjects from 9 families with heritable PAH and applied gene-based association analysis with 9 index patients and
300 PAH-free controls.
Results: A burden of rare variants in BMPR2 significantly contributed to the risk of the disease (p = 6.0 × 10−8). Eight
of nine families carried four previously reported single nucleotide variants and four novel insertion/deletion
variants in the gene. One of the novel variants was a large 6.5 kilobase-deletion. In the remaining one family,
the patient carried a pathogenic variant in a member of potassium channels, KCNK3, which was the first
replicative finding of channelopathy in an Asian population.
Conclusions: The variety of rare pathogenic variants suggests that gene-based association analysis using
genome-wide sequencing data from increased number of samples is essential to tracing the genetic
heterogeneity and developing an appropriate panel for genetic testing.
Keywords: Clinical genetic testing, Gene-based association study, Next generation sequencing, Pulmonary
arterial hypertension
Background
Pulmonary arterial hypertension (PAH, MIM #178600)
is a rare vascular lung disease presenting increased
pulmonary vascular resistance and elevation of mean
pulmonary arterial pressure, leading to a grave prognosis
of right heart failure without treatment. While survival
rates are increasing with a number of recently developed
treatments such as epoprostenol, the optimal care of
patients with these therapies is unclear due to pheno-
typic variations and genetic backgrounds.
Despite the complex etiology of PAH due to incomplete
penetrance and genetic heterogeneity, multiple genes that
cause PAH have been discovered during the last few de-
cades. BMPR2 variants have been identified in not only
>70% of heritable PAH (HPAH), but also 10–40% of idio-
pathic PAH (IPAH) [1–6]. Variants of other genes includ-
ing KCNK3, ACVRL1, ENG, CAV1, and the SMAD family
are also rare causes of PAH [7–11]. Furthermore, com-
mon variants in CBLN2 and KCNA5 were also reported to
be associated with the risk of PAH in European Cauca-
sians [12, 13].
Although identification of individuals who carry gen-
etic variants that increase the risk of developing PAH
offers an opportunity for earlier diagnosis and finding a
therapeutic strategy, the majority of previous studies was
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only focused on the protein coding regions of the most
frequently mutated gene BMPR2 with the use of conven-
tional methods such as Sanger sequencing [6, 14]. Thus, for
the patients who have no mutation in BMPR2, i.e., around
30% of HPAH and 60–90% of IPAH, another approach,
which is practical for multiple genes, is necessary. Consider-
ing that current state-of-the-art sequencing technologies
allow us to access exome- and genome-wide variants with
reasonable costs, unbiased screening of pathogenic variants
is beneficial to continue expanding the genetic diagnosis
catalogue. However, conventional segregation-based ap-
proaches, e.g., linkage analysis, do not have enough power
to pinpoint the true pathogenic variants from these
genome-wide candidate variants without functional evalua-
tions, especially for diseases with phenotypic and genetic
heterogeneity. In this study, applying a gene-based associ-
ation test, we statistically evaluate the significance of rare
variant enrichment in genes responsible for PAH. The strat-
egy we employed here would be useful to unbiasedly eluci-
date the pathogenicity of multiple rare variants arising from




We consecutively enrolled five families with PAH and
four individual cases with a family history of PAH to this
study (Fig. 1). The patients have been diagnosed in the
National Hospital Organization Okayama Medical
Center between 1996 and 2014. All subjects who partici-
pated in our study were approved by the Institutional
Review Board of our institutes in which donors gave
written informed consent in accordance with institu-





































































































Fig. 1 Segregation of the pathogenic variants identified in 9 familial PAH. a Eight families carried BMPR2 variants and one family carried a KCNK3
variant. Nucleotide and amino acid changes for BMPR2 and KCNK3 are described on NM_001204.6 and NM_002246.2, respectively. Index patients
of each family are pointed with arrows. The subjects whose DNAs were available are indicated in plus signs. b All the possible pathogenic variants
discovered in the eight PAH families were located before or in the kinase domain. Four previously reported and four novel variants were indicated
with black and red letters, respectively
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Next-generation sequencing and data analysis
To understand comprehensive genetic background of these
9 PAH families, we applied whole exome- or genome-
sequencing to 12 patients and 5 healthy family members
whose DNA were available (Fig. 1 and Additional file 1:
Table S1). For the exome sequencing, DNA fragments
were enriched by SureSelectXT Human All Exon v4 +
UTR (Agilent Technologies, Santa Clara, CA, USA) and
then applied to SOLiD™ 5500XL sequencer (Thermo Fisher
Scientific inc., Waltham, MA, USA). The whole genome
sequencing was conducted with the Illumina HiSeq X
sequencer (Illumina Inc., San Diego, CA, USA). After
aligning the sequence reads onto the reference genome
(NCBI Build 37) using the Burrows-Wheeler Aligner [15],
downstream processes including the duplication removal,
the recalibration of base quality values, the local realign-
ment, the variant call, and the variant quality score recali-
bration were analyzed using GATK [16]. The variants were
called with an exome sequencing data set of 300 control
samples obtained from the Human Genome Variation
Database (accession ID: HGV0000004) [17]. The resulting
VCF file has been deposited on the same database under
accession HGV0000005.
Quality control for association study
After removing variants that were assigned as low qual-
ity by the GATK VariantRecalibrator, additional filters
were applied to extract high quality variants such as low
call rate (<0.9), excessive strand bias (FS > 50), haplotype
score (> 5), deviation from Hardy-Weinberg equilibrium
(InbreedingCoeff > 0.3), mapping quality of the reads
(MQ < 35), excess of zero mapping quality (MQ0 > 100),
bias of mapping quality between reference and alterna-
tive alleles (MQRankSum < 13), coverage over sample
(DP/sample < 10), positional bias of the reads (ReadPos-
RankSum > 5), quality over depth (QD < 8), and low
LOD score (VQSLOD < 0). For the gene-based associ-
ation analysis, we selected likely protein damaging
variants (premature termination, splice site, missense, and
indels on exons) to perform the Variable Threshold (VT)
test [18] implemented in Variant Association Tools [19].
Annotation and screening of pathogenic variants
All identified variants were annotated using ANNOVAR
[20]. Candidate pathogenic variants were screened ac-
cording to the registrations and frequencies of the vari-
ants in the public databases: dbSNP (Build 147) [21],
The 1000 Genomes (November 2010 data release) [22],
The 10Gen Data Set (version 1.04) [23], NHLBI GO
Exome Sequencing Project (ESP6500SI) [24], the Human
Genetic Variation Database [17] or ClinVar [25]. For
missense variants, PolyPhen-2 [26] and Mutation Taster
[27], LRT [28] and PhyloP [29] score were obtained from
the dbNSFP database [30]. Damaging effects of splice
site variants were evaluated with MaxEntScan [31] and
Human Splicing Finder [32].
Results
Gene-based association study
To identify genes responsible for the pathogenesis of
PAH, we applied a gene-based association test (Variable
Threshold test [18]) to the 60,367 damaging variants ex-
tracted from the nine PAH patients and the 300 control
samples. These variants were located within 10,744 gene
regions. Despite the small sample size, the burden of as-
sociation between BMPR2 and PAH was highly signifi-
cant (p = 6.0 × 10−8) compared to the genome-wide
significance threshold (p < 2.4 × 10−6) after Bonferroni
correction for approximately 21,000 genes (Fig. 2). No
other gene was found beyond the threshold.
Identifying the pathogenic variants
The spectrum of rare variants found in BMPR2 is sum-
marized in Table 1. Of the nine families, four carried
previously reported single nucleotide pathogenic variants
(2 missenses, 1 nonsense, and 1 splice site) [1, 4, 6] and
four carried novel insertions/deletions (indels) in this
gene (88.9%). One of the novel indels was a large dele-
tion of 6.5 kilobases in length by which one allele lacks
the entire region of exon 3 (Additional file 2: Figure S1).
Two variants are suspected to be pathogenic although
showing incomplete penetrance, since clinically un-
affected subjects in the families harbored the same vari-
ants found in the patients (Table 1). There were no
Fig. 2 Gene-based association analysis. Quantile-quantile plot for VT
test of the nine cases and 300 controls are shown. BMPR2 was the
only gene that surpassed the genome-wide significance threshold
for 21,000 genes
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BMPR2 variants observed in the remaining one of nine
families, but we identified one heterozygous missense
variant (p.Gly203Asp) in KCNK3 by screening the previ-
ously reported pathogenic variants [25]. This variant was
shown to disrupt the ion-channel function by patch-
clump analysis [11]. None of the pathogenic variants we
identified was observed in the 300 control samples or in
the public database for the Japanese population [17]. Of
these, all three missense variants were occurred at highly
conserved nucleotides among vertebrates and were as-
sumed to be damaging to the protein function by at least
three in silico prediction programs [26–29] (Table 1).
Discussion
To our knowledge, this is the first report of gene-based
genome-wide association analysis of HPAH. A burden of
rare variants in BMPR2 significantly contributes to risk
of the disease (p = 6.0 × 10−8). The approach robustly de-
tected the gene having a large effect on the pathogenesis
of PAH, despite the genetic heterogeneity. Eight
probands in the nine families harbored possible patho-
genic variants in BMPR2. Half of these variants were
novel indels. One of the novel indels was a large 6.5 kilo-
base deletion spanning the entire region of exon 3.
Another novel indel was a three base insertion
(NM_001204.6:c.1277-10_1277-9insGGG) in intron 9
(Additional file 3: Figure S2). Although we could not
dismiss that this insertion has no responsibility to the
disease pathogenicity, a potential creation of a new splice
acceptor site by this insertion was strongly suggested
from the multiple splice site prediction tools (Table 1,
Additional file 4: Figure S3 and Additional file 5: Figure
S4) [31, 32]. The remaining one patient harbored a mis-
sense variant in KCNK3, which was the first replicative
finding of channelopathy in Japanese population. Among
the nine families, all variants identified here were mutu-
ally exclusive, suggesting that the variants have origi-
nated from independent genetic founder events.
Patients who suffered from chronic lung diseases such
as chronic obstructive pulmonary disease (COPD) and
pulmonary fibrosis are prone to pulmonary hypertension
(PH) development. They are categorized as Group 3 in
the latest guidelines [33]. Most patients with COPD
develop mild PH but 3–5% of them show a further rise in
mean pulmonary arterial pressure >35 mmHg. It is un-
known how “severe PH-COPD”, formerly known as “out-
of-proportion PH” is induced. Furthermore, the PAH-
approved drugs are yet to be approved for the patients
with Group 3 PH. In this study, a male patient (OM0195
in HPAH005) had been treated at another hospital for
COPD. He was later diagnosed with PH and referred to
our hospital. This patient could be categorized as “severe
PH-COPD”, if none of his family members developed
PAH. Since we had treated his daughter for IPAH at our
hospital, we clinically diagnosed them as HPAH. Genetic
testing revealed an in-frame-deletion (c.1443_1445del-
GAA) in BMPR2 in both patients. Underlying genetic pre-
disposition might be one of the reasons for developing
“severe PH-COPD”. Given our finding and a similarity of
morphological appearance of vascular lesions between
Group 1 and “severe PH-COPD” patients [33], PAH-
approved drug treatments tailored to genetic diagnosis
could well be a therapeutic strategy for such patients.
Conclusions
According to the genetic testing registry at the National
Institutes of Health, the available panels for clinical
genetic testing for PAH do not include KCNK3 and the
detection methods are limited. Considering that patho-
genic variants could occur within or spanning non-
coding regions with a variety of sizes, the sequencing of
the entire region of candidate genes is recommended to
further understand the genetic factors relevant to PAH.
This strategy will be essential for improving genetic
diagnosis and counseling for PAH.
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Additional file 1: Table S1. Summary of mapping statistics. (PDF 22 kb)
Additional file 2: Figure S1. Large deletion found in the patient in
family 8. (a) The large deletion was supported by depth of coverage and
discordant paired-end reads. (b) The length of the deletion was approximately
6.5 kilobases and spanned the entire region of exon 3. Breakpoints of the large
heterozygous deletion were located in the Alu repeat sequences, which were
supported by read depths and paired-end reads spanning the long region.
(PDF 529 kb)
Additional file 3: Figure S2. Possible pathogenic variants found in the
intron of BMPR2 in family 4. A rare three base insertion (GGG) at 10 bases
upstream from exon 10 creates identical sequences around the canonical
splicing site (ACAGGG). By the insertion, an out-of-frame protein could be
translated due to the new splice acceptor site. (PDF 411 kb)
Additional file 4: Figure S3. Creation of the new splice acceptor site
by the three base insertion (NM_001204.6:c.1277-10_1277-9insGGG)
predicted from in silico programs. (PDF 218 kb)
Additional file 5: Figure S4. Disruption of wild type acceptor site by
the single nucleotide variants (c.853-2A > G) predicted from in silico
programs. (PDF 184 kb)
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